Cytori Therapeutics Inc. (NASDAQ:CYTX)’s share price fell 1.4% during mid-day trading on Wednesday . The stock traded as low as $2.14 and last traded at $2.16, with a volume of 149,626 shares trading hands. The stock had previously closed at $2.19.

Several brokerages have weighed in on CYTX. Maxim Group set a $5.00 target price on shares of Cytori Therapeutics and gave the company a “buy” rating in a research note on Friday, August 5th. Zacks Investment Research upgraded shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Monday, August 1st. Finally, Roth Capital restated a “buy” rating and issued a $11.00 target price on shares of Cytori Therapeutics in a research note on Tuesday, June 28th.

The stock’s market capitalization is $41.60 million. The firm’s 50 day moving average is $2.07 and its 200 day moving average is $2.75.

Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.04. The firm had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $2.50 million. During the same quarter in the prior year, the company posted ($0.06) EPS. The business’s revenue was down 31.3% on a year-over-year basis. Analysts anticipate that Cytori Therapeutics Inc. will post ($1.48) EPS for the current year.

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.